Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fluvastatin Sodium

FDA-approved product (capsule, oral), marketed as Fluvastatin Sodium, Lescol, Lescol Xl.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Fluvastatin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Familial hypercholesterolemia
  • Hypercholesterolemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hmg coa reductase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fluvastatin Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluvastatin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome

    NCT00309257 · start 2004-01

    Registered record
    Registry ID
    NCT00309257
    Conditions
    Alport Syndrome
    Interventions
    ACE I, ATA II and Statins; Benazepril, Valsartan and Fluvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-01
    Completion
    2009-10
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlport Syndrome
    InterventionACE I, ATA II and Statins; Benazepril, Valsartan and Fluvastatin
    PhasePhase 2
    Registry statusCompleted

  • Fluvastatin in the Therapy of Acute Coronary Syndrome

    NCT00171275 · start 2003-11

    Registered record
    Registry ID
    NCT00171275
    Conditions
    Coronary Disease; Myocardial Infarction
    Interventions
    Fluvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-11
    Completion
    Not recorded
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Disease; Myocardial Infarction
    InterventionFluvastatin
    PhasePhase 4
    Registry statusCompleted

  • High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

    NCT00127218 · start 2003-09

    Registered record
    Registry ID
    NCT00127218
    Conditions
    Atherosclerosis; Cardiovascular Disease
    Interventions
    any statin; niacin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-09
    Completion
    2008-12
    Enrolment
    145

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis; Cardiovascular Disease
    Interventionany statin; niacin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Statin Therapy in Asymptomatic Aortic Stenosis

    NCT00176410 · start 2003-01

    Registered record
    Registry ID
    NCT00176410
    Conditions
    Aortic Valve Stenosis
    Interventions
    fluvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2003-01
    Completion
    2009-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAortic Valve Stenosis
    Interventionfluvastatin
    PhasePhase 2
    Registry statusUnknown

  • Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia

    NCT00171236 · start 2001-10

    Registered record
    Registry ID
    NCT00171236
    Conditions
    Heterozygous Familial Hypercholesterolemia; Mixed Dyslipidemia
    Interventions
    Fluvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-10
    Completion
    2005-03
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeterozygous Familial Hypercholesterolemia; Mixed Dyslipidemia
    InterventionFluvastatin
    PhasePhase 3
    Registry statusCompleted